Regulators are more frequently expecting co-validation of imaging or soluble biomarkers, like CA-125 and emerging multiplex panels, for theranostic ovarian platforms [209], evaluated in conjunction with the nanomedicine consistent with the broader shift toward imaging-based companion diagnostics and biomarker-guided theranostics in ovarian cancer [210]. The gene discussed is MUC16; the disease is ovarian cancer.